Recent data showed that in patients undergoing radical resection of non‐small cell lung cancer (NSCLC), the serum of patients treated with propofol had a lower concentration of tumour angiogenesis‐related factors, such as vascular endothelial growth factor (VEGF) and transforming growth factor beta, than that in the sevoflurane group.27 Here, VEGFA is linked to lung cancer.